[{"id":"ee309a82-4f0b-426f-a0b1-deeeabf2fd59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04802161","created_at":"2021-03-17T15:57:34.517Z","updated_at":"2025-02-25T16:32:23.537Z","phase":"Phase 2","brief_title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","source_id_and_acronym":"NCT04802161","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2","pipe":" | ","alterations":" Chr del(11q)","tags":["RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"61e57503-680e-4667-ac9e-45a1209fdaaf","acronym":"TT4B","url":"https://clinicaltrials.gov/study/NCT00734877","created_at":"2021-01-18T02:46:06.475Z","updated_at":"2025-02-25T14:55:10.781Z","phase":"Phase 3","brief_title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","source_id_and_acronym":"NCT00734877 - TT4B","lead_sponsor":"University of Arkansas","biomarkers":" TP53","pipe":" | ","alterations":" TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dexamethasone • thalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-07-03"},{"id":"2c66d4b7-1c2e-4cd1-a61a-2f452cfb4042","acronym":"","url":"https://clinicaltrials.gov/study/NCT06470464","created_at":"2025-02-26T14:17:59.459Z","updated_at":"2025-02-26T14:17:59.459Z","phase":"Phase 2","brief_title":"Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor","source_id_and_acronym":"NCT06470464","lead_sponsor":"Shandong First Medical University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • epirubicin • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/16/2024","primary_completion_date":" 06/16/2024","study_txt":" Completion: 06/16/2024","study_completion_date":" 06/16/2024","last_update_posted":"2024-06-24"},{"id":"0047622f-f69f-43a0-88ba-95ea158c26de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06279351","created_at":"2024-02-29T04:33:08.905Z","updated_at":"2024-07-02T16:35:17.163Z","phase":"Phase 2","brief_title":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","source_id_and_acronym":"NCT06279351","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • thalidomide • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-28"},{"id":"cb1eef0a-e163-46d8-8f49-52a6658d6c5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06256627","created_at":"2024-02-13T20:25:59.985Z","updated_at":"2024-07-02T16:35:19.538Z","phase":"","brief_title":"The Maintenance Treatment of \"ITIVA\" in AML Patients","source_id_and_acronym":"NCT06256627","lead_sponsor":"Henan Cancer Hospital","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • thalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-02-13"},{"id":"151a9d64-fe72-45af-9af7-b34da084781c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01661400","created_at":"2021-01-18T07:10:35.641Z","updated_at":"2024-07-02T16:35:21.403Z","phase":"Phase 1","brief_title":"Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors","source_id_and_acronym":"NCT01661400","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • thalidomide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/26/2012","start_date":" 10/26/2012","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 12/27/2023","study_completion_date":" 12/27/2023","last_update_posted":"2024-01-31"},{"id":"295b0561-593e-4af2-bcb7-0b0537450f29","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896737","created_at":"2021-01-18T19:11:30.460Z","updated_at":"2024-07-02T16:35:37.895Z","phase":"Phase 2","brief_title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","source_id_and_acronym":"NCT03896737","lead_sponsor":"European Myeloma Network","biomarkers":" IGH","pipe":" | ","alterations":" IGH translocation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 401","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-09-07"},{"id":"1c785025-f43b-4883-8f63-f4781a546652","acronym":"","url":"https://clinicaltrials.gov/study/NCT00869232","created_at":"2021-01-18T03:19:09.867Z","updated_at":"2024-07-02T16:35:40.540Z","phase":"Phase 2","brief_title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","source_id_and_acronym":"NCT00869232","lead_sponsor":"University of Arkansas","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-08-09"},{"id":"c38bf8bf-b726-4684-ac2b-3f7adfe5aeb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01242267","created_at":"2021-01-18T05:00:11.712Z","updated_at":"2025-02-25T14:56:08.019Z","phase":"Phase 1/2","brief_title":"Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","source_id_and_acronym":"NCT01242267","lead_sponsor":"Hackensack Meridian Health","biomarkers":" BCL2 • CD34","pipe":"","alterations":" ","tags":["BCL2 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • thalidomide • melphalan • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 05/11/2010","start_date":" 05/11/2010","primary_txt":" Primary completion: 01/20/2016","primary_completion_date":" 01/20/2016","study_txt":" Completion: 01/20/2016","study_completion_date":" 01/20/2016","last_update_posted":"2023-01-02"},{"id":"907ac024-6f24-4eec-86a3-da0fa9aea08f","acronym":"THRiL","url":"https://clinicaltrials.gov/study/NCT01125176","created_at":"2021-01-18T04:28:01.185Z","updated_at":"2025-02-25T14:31:56.393Z","phase":"Phase 2","brief_title":"Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL","source_id_and_acronym":"NCT01125176 - THRiL","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 03/30/2012","start_date":" 03/30/2012","primary_txt":" Primary completion: 12/20/2018","primary_completion_date":" 12/20/2018","study_txt":" Completion: 12/29/2020","study_completion_date":" 12/29/2020","last_update_posted":"2022-01-21"},{"id":"01402a98-429f-4cf2-b69d-75ccff5f707c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05198856","created_at":"2022-01-20T15:53:53.558Z","updated_at":"2024-07-02T16:36:18.276Z","phase":"Phase 1/2","brief_title":"Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC","source_id_and_acronym":"NCT05198856","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • thalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/10/2024","primary_completion_date":" 03/10/2024","study_txt":" Completion: 12/10/2024","study_completion_date":" 12/10/2024","last_update_posted":"2022-01-20"},{"id":"6bf16149-61da-4e07-89da-5c263485c4ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT00075829","created_at":"2021-01-18T00:12:12.016Z","updated_at":"2024-07-02T16:36:22.026Z","phase":"Phase 3","brief_title":"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)","source_id_and_acronym":"NCT00075829","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 710","initiation":"Initiation: 12/01/2003","start_date":" 12/01/2003","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2021-11-01"},{"id":"c52db608-0147-4e7b-a4a9-1aa8cea334b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04382300","created_at":"2021-01-18T21:09:42.983Z","updated_at":"2024-07-02T16:36:35.432Z","phase":"Phase 2","brief_title":"Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions","source_id_and_acronym":"NCT04382300","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • thalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2021-01-28"},{"id":"31f15265-1220-4c1c-9b23-9c70cc30767a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00049374","created_at":"2021-01-18T00:05:03.471Z","updated_at":"2024-07-02T16:36:54.498Z","phase":"Phase 2","brief_title":"Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT00049374","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • thalidomide • Genasense (oblimersen)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 09/01/2002","start_date":" 09/01/2002","primary_txt":" Primary completion: 01/01/2006","primary_completion_date":" 01/01/2006","study_txt":" Completion: 01/01/2006","study_completion_date":" 01/01/2006","last_update_posted":"2019-10-17"},{"id":"490db03e-91ee-4e4c-afc6-b57bed9c3f1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00041080","created_at":"2021-01-18T00:02:59.271Z","updated_at":"2024-07-02T16:36:57.589Z","phase":"Phase 3","brief_title":"Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00041080","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • thalidomide • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 02/01/2003","start_date":" 02/01/2003","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 01/01/2011","study_completion_date":" 01/01/2011","last_update_posted":"2019-07-30"},{"id":"4b3c5a90-7c09-4d7e-a807-bdb458ab8a9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03062800","created_at":"2021-01-18T15:05:07.285Z","updated_at":"2024-07-02T16:36:59.087Z","phase":"Phase 2","brief_title":"Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)","source_id_and_acronym":"NCT03062800","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" EGFR • VEGFA","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 232","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-06-05"},{"id":"39d94fa9-761b-4f7d-9a9b-52a865613e4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777930","created_at":"2021-01-18T18:41:15.246Z","updated_at":"2024-07-02T16:37:04.517Z","phase":"Phase 4","brief_title":"The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol","source_id_and_acronym":"NCT03777930","lead_sponsor":"Shenzhen Fifth People's Hospital","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e thalidomide • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 06/10/2021","study_completion_date":" 06/10/2021","last_update_posted":"2018-12-19"},{"id":"ff0dc726-b22c-4eec-95db-9406c65225ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT00038246","created_at":"2021-01-18T00:02:12.994Z","updated_at":"2025-02-25T14:22:50.034Z","phase":"Phase 1/2","brief_title":"Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma","source_id_and_acronym":"NCT00038246","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • thalidomide • Emcyt (estramustine)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/01/2000","start_date":" 10/01/2000","primary_txt":" Primary completion: 02/01/2004","primary_completion_date":" 02/01/2004","study_txt":" Completion: 12/01/2004","study_completion_date":" 12/01/2004","last_update_posted":"2018-10-31"},{"id":"48bc3925-f5dd-46b4-b5d5-b7d989e551a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00151281","created_at":"2021-01-18T00:30:54.507Z","updated_at":"2024-07-02T16:37:09.373Z","phase":"Phase 2","brief_title":"Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma","source_id_and_acronym":"NCT00151281","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD20 • CCND1 • CD5 • MME • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • prednisone • thalidomide • Matulane (procarbazine hydrochloride)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2004","start_date":" 11/01/2004","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 04/07/2011","study_completion_date":" 04/07/2011","last_update_posted":"2018-06-28"},{"id":"e30983bd-3ef7-4a75-984a-51ef448f0210","acronym":"CSWOG002","url":"https://clinicaltrials.gov/study/NCT03341494","created_at":"2021-01-18T16:30:15.849Z","updated_at":"2024-07-02T16:37:16.377Z","phase":"Phase 2","brief_title":"EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide","source_id_and_acronym":"NCT03341494 - CSWOG002","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 128","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2017-11-14"},{"id":"b961f304-ce21-45a7-888f-5aca492032ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT03318835","created_at":"2021-01-18T16:23:22.874Z","updated_at":"2024-07-02T16:37:16.909Z","phase":"Phase 3","brief_title":"Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients","source_id_and_acronym":"NCT03318835","lead_sponsor":"Fudan University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 162","initiation":"Initiation: 08/22/2017","start_date":" 08/22/2017","primary_txt":" Primary completion: 08/22/2020","primary_completion_date":" 08/22/2020","study_txt":" Completion: 08/22/2020","study_completion_date":" 08/22/2020","last_update_posted":"2017-10-24"},{"id":"18a31d2f-4fc8-4aec-b7b2-91da3287927e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03273452","created_at":"2021-01-18T16:10:03.757Z","updated_at":"2024-07-02T16:37:17.600Z","phase":"Phase 2","brief_title":"Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)","source_id_and_acronym":"NCT03273452","lead_sponsor":"Qingdao University","biomarkers":" CD20 • PD-1 • BCL6 • CD4 • CXCL13 • MME • CR1","pipe":"","alterations":" ","tags":["CD20 • PD-1 • BCL6 • CD4 • CXCL13 • MME • CR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • prednisone • Epidaza (chidamide) • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2017-09-25"},{"id":"1b940136-1411-4455-9d96-af20cf1be948","acronym":"","url":"https://clinicaltrials.gov/study/NCT00899080","created_at":"2021-01-18T03:27:19.009Z","updated_at":"2024-07-02T16:37:22.051Z","phase":"","brief_title":"Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide","source_id_and_acronym":"NCT00899080","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CTSG","pipe":"","alterations":" ","tags":["CTSG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/04/2008","start_date":" 07/04/2008","primary_txt":" Primary completion: 08/04/2008","primary_completion_date":" 08/04/2008","study_txt":" Completion: 08/04/2008","study_completion_date":" 08/04/2008","last_update_posted":"2017-05-17"},{"id":"8f7ac914-47b5-4a49-9302-922cc84999fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02778893","created_at":"2021-01-18T13:37:57.238Z","updated_at":"2024-07-02T16:37:31.815Z","phase":"Phase 4","brief_title":"Conmana Combined With Thalidomide to Treat NSCLC","source_id_and_acronym":"NCT02778893","lead_sponsor":"Henan Provincial People's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib) • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 67","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/01/2017","primary_completion_date":" 03/01/2017","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2016-05-20"}]